SEC Form 4 · accession 0000907654-26-000069

Oruka Therapeutics, Inc. · ORKA

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Chief Operating Officer

Period of report

Jul 1, 2026

Accepted (ET)

Jul 1, 2026 · 7:58 pm EDT

Rule 10b5-1 plan

yes — trade under a plan

Issuer CIK

0000907654

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock	Jul 1, 2026	M	5,000	$7.80	A	241,384	D
Common Stock^F2	Jul 1, 2026	S	2,237	$93.8457	D	239,147	D
Common Stock^F3	Jul 1, 2026	S	2,263	$94.7458	D	236,884	D
Common Stock^F4	Jul 1, 2026	S	500	$95.472	D	236,384	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Employee Warrant (right to buy)^F5	$7.80	Jul 1, 2026	M	5,000	D	—	Jul 14, 2034	Common Stock	5,000	79,996	D

F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025.
F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.29 to $94.26, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4.
F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.38 to $95.19, inclusive.
F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $95.40 to $95.51, inclusive.
F5The warrant vests as to 1/4 of the underlying shares on April 3, 2025 and as to 1/48 of the underlying shares monthly from April 3, 2025.